One To Watch
Tenax Therapeutics
Company Overview
A Phase III-stage pharmaceutical company developing TNX-103, an oral formulation of levosimendan, for pulmonary hypertension with heart failure with preserved ejection fraction, now navigating an enriched-population regulatory strategy after a pivotal trial miss. Tenax Therapeutics (Nasdaq: TENX) holds global rights to levosimendan for PH-HFpEF, a disease area with no approved therapy in the United States. The company's entire near-term value rests on a single asset and on whether FDA and EMA will accept a subgroup-based path to approval.
Headquarters and Global Presence
Tenax Therapeutics is headquartered in Chapel Hill, North Carolina. The company is listed on Nasdaq under the ticker TENX and operates as a US-focused development-stage business, with no commercial operations currently in place.
Founding and History
Chris Giordano has served as CEO and a board member since July 2021 and as President since October 2021, shaping the company's pivot to PH-HFpEF as its central thesis. The FDA cleared the investigational new drug application for TNX-103 in PH-HFpEF in November 2023, and the registrational LEVEL program was expanded in March 2025. Tenax previously pursued an oral formulation of imatinib for pulmonary arterial hypertension but deprioritized that program; as of 2026, no significant imatinib development is ongoing.
Therapy Areas and Focus
Tenax focuses on cardiovascular and pulmonary disease, specifically the underserved overlap condition PH-HFpEF, where elevated pulmonary pressures complicate heart failure with preserved ejection fraction. The condition carries high morbidity and no approved US therapy, creating a genuine unmet need that regulators and clinicians have acknowledged.
The commercial case, however, now hinges on a subset of more severely impaired patients, those with a baseline six-minute walk distance below 333 meters, rather than the broader enrolled population.
Technology Platforms and Modalities
TNX-103 is an oral formulation of levosimendan, a calcium sensitizer and ATP-sensitive potassium channel opener originally developed by Orion Pharma and first approved intravenously in Sweden in 2000 as Simdax for acutely decompensated heart failure. The key reformulation thesis is chronic oral dosing rather than episodic intravenous infusion, shifting levosimendan's hemodynamic benefits into a maintenance setting.
Levosimendan has never been approved in the United States. Tenax's argument is that its dual mechanism, improving myocardial contractility without increasing oxygen demand while also reducing right ventricular afterload, addresses the distinct pathophysiology of PH-HFpEF.
Key Pipeline and Programs
TNX-103 is the company's sole active clinical asset. It is an oral small-molecule formulation of levosimendan, evaluated in the Phase III LEVEL trial in PH-HFpEF across 241 randomized patients (120 TNX-103, 121 placebo).
The trial did not meet its primary endpoint: six-minute walk distance improved by only 3.5 meters versus placebo (p=0.63), and the Kansas City Cardiomyopathy Questionnaire total symptom score improved by just 0.1 points.
The prespecified subgroup with baseline walk distance below 333 meters (n=119) told a different story: a 26.3-meter improvement versus placebo (95% CI 6.0-46.7, p=0.0112, nominal). NT-proBNP fell 49% more on TNX-103 than placebo (p less than 0.0001, nominal), and right ventricular systolic pressure declined 3.5 mmHg versus placebo (p=0.0045, nominal).
Serious adverse events were 10.8% on TNX-103 versus 10.7% on placebo, with no new safety signals, which is the one clean result from LEVEL and preserves the option for a redesigned trial in a more impaired population.
Recent Developments
On 10 August 2026, Tenax announced topline Phase III LEVEL results for TNX-103; the trial failed its primary and key secondary endpoints. The following day, as reported by The Pharma Letter, shares fell 90% to $1.38.
Tenax simultaneously announced it intends to request a Type C meeting with the FDA to present the full LEVEL dataset, and to seek scientific consultation from the EMA, with both discussions centering on an enriched-population strategy focused on patients with lower baseline walk distances.
Principal investigator Sanjiv Shah, MD, Director of the HFpEF Program at Northwestern University, characterized the exercise capacity improvement as concentrated in the more severely impaired subgroup, lending external scientific weight to the regulatory pivot.
Key Personnel
Chris Giordano serves as President and Chief Executive Officer. He has held the CEO role and a board seat since July 2021 and assumed the President title in October 2021.
Stuart Rich, MD, serves as Chief Medical Officer. Following the LEVEL readout, Rich stated that the prespecified subgroup analyses demonstrate a meaningful beneficial treatment effect, framing the regulatory argument the company will carry into its FDA and EMA consultations.
So-Young Kim, MD, serves as Executive Vice President of Clinical Development and Strategy, with Douglas Hay, PhD, serving as Executive Vice President of Regulatory Affairs, a pairing that will be central to executing the post-LEVEL regulatory plan.
Strategic Partnerships
Tenax holds global rights to levosimendan for PH-HFpEF. No licensing partners, co-development agreements, or named institutional investors are identified in available disclosures. The company's regulatory engagement now involves the FDA and EMA directly, with both agencies being approached for scientific guidance on the enriched-population path forward.
FAQ Section
The LEVEL trial missed its primary endpoint in the full 241-patient population, but a prespecified subgroup of 119 patients with baseline six-minute walk distance below 333 meters showed a 26.3-meter improvement versus placebo (p=0.0112, nominal). Biomarker data reinforced the signal: NT-proBNP fell 49% more on TNX-103 than placebo, and right ventricular systolic pressure dropped 3.5 mmHg. Tenax is arguing to FDA and EMA that enrolling a more impaired population from the outset would concentrate the treatment effect and support a registrational trial that can meet its endpoints.
PH-HFpEF combines elevated pulmonary pressures with heart failure in which the left ventricle retains normal systolic function, a mechanistically complex overlap that has resisted therapies designed for either condition alone. The heterogeneity of the population enrolled in LEVEL, spanning a wide range of baseline functional capacity, likely diluted the treatment effect in the overall analysis. No therapy is currently approved in the United States specifically for PH-HFpEF, which is why regulators and cardiologists have shown interest in the condition despite the difficulty of running registrational trials in it.
Intravenous levosimendan (Simdax, approved in Sweden in 2000) is used for episodic infusions in acutely decompensated heart failure rather than as chronic therapy. TNX-103 reformulates the same molecule for daily oral dosing, aiming to sustain the hemodynamic benefits, reduced right ventricular afterload and improved myocardial contractility without increased oxygen demand, in a maintenance setting. That shift in dosing route is the core of Tenax's repositioning argument, though it also means the clinical evidence base for the oral form has to be built entirely from scratch in the US context.
In 241 randomized patients, TNX-103 improved six-minute walk distance by only 3.5 meters versus placebo (p=0.63), a result that was not statistically significant, and the Kansas City Cardiomyopathy Questionnaire total symptom score improved by just 0.1 points. The subgroup with the lowest baseline function (n=119, walk distance below 333 meters) showed a 26.3-meter improvement (95% CI 6.0-46.7, p=0.0112, nominal), alongside a 49% greater reduction in NT-proBNP. Safety was clean: serious adverse events were essentially identical across arms (10.8% versus 10.7%), with no new signals.
As of 2026, PH-HFpEF is the entirety of Tenax's active pipeline. The company previously pursued an oral imatinib formulation for pulmonary arterial hypertension but deprioritized that Phase III program and no significant imatinib activity is ongoing. The company's scientific focus is on the cardiovascular-pulmonary overlap, specifically conditions where right heart function and pulmonary hemodynamics intersect with structural heart disease.
Tenax has completed one Phase III trial and failed its primary endpoint, leaving the company in a liminal regulatory position. It has announced plans to request a Type C meeting with the FDA and parallel scientific consultation from the EMA, both focused on an enriched-population design. Whether regulators will support a second registrational study, and on what terms, is the central question that will determine whether the program continues or is abandoned. The 90% share price drop to $1.38 on 11 August 2026 reflects the market's assessment of those odds.
The post-LEVEL period is defined by a narrow set of binary outcomes. Key watchpoints include:
- FDA Type C meeting outcome: whether the agency endorses an enriched-population trial design or considers the LEVEL data insufficient to support further registrational work.
- EMA scientific consultation: a positive European signal could open a parallel development path and provide leverage in US discussions.
- Financial runway: with shares at $1.38 and no commercial revenue, Tenax's ability to fund a redesigned trial is the most immediate practical constraint.
- Subgroup robustness: the 26.3-meter improvement in n=119 patients is a prespecified but post-hoc-appearing result; FDA will scrutinize whether it reflects a true predictive biomarker or a chance finding in a small cohort.
- Competitive landscape: the PH-HFpEF space is attracting increasing interest; a prolonged regulatory process risks ceding ground to better-capitalized programs.
Today's issue
| Headless Content Management with Blaze